Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total value of $316,787.52.
• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $43.80, for a total value of $263,588.40.

Enliven Therapeutics Trading Down 1.1%

Shares of Enliven Therapeutics stock traded down $0.68 on Wednesday, reaching $59.39. 939,429 shares of the stock were exchanged, compared to its average volume of 1,258,195. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The firm has a market capitalization of $4.35 billion, a PE ratio of -35.56 and a beta of 0.27. The business has a fifty day moving average price of $51.90 and a two-hundred day moving average price of $41.38.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Research analysts expect that Enliven Therapeutics, Inc. will post -1.67 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ELVN. Guggenheim decreased their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. The Goldman Sachs Group raised their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Commodore Capital LP lifted its holdings in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the last quarter. BlackRock Inc. acquired a new stake in Enliven Therapeutics during the second quarter worth $221,255,000. Vestal Point Capital LP increased its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares during the period. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after buying an additional 418,673 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after buying an additional 142,378 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.